



# Drug Hypersensitivity and Innate Immune Response Group

Publications: 21  
 Impact Factor: 74.749  
 Q1: 8



## Research Activity

### Publications

- Alfageme F, Salguero I, Nojera L, Suárez ML, Rouston G. Increased marginal stiffness differentiates infiltrative from noninfiltrative cutaneous basal cell carcinomas in the facial area: A prospective study. *J Ultras Med.* 2019; 38(7): 1841-5. Article. IF: 1.759; Q2
- Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. *Drug Safety.* 2019; 42(8): 973-92. Review. IF: 3.442; Q2
- Bygum A, Caballero T, Grumach AS, Longhurst HJ, Bouillet L, Aberer W, Zanichelli A, Botha J, Andresen I, Maurer M, Grumach AS, Bygum A, Delaunay CB, Boccon-Gibod I, Bouillet L, Coppere B, Du Thanh A, Dzviga C, Fain O, Goichot B, Gompel A, Guez S, Jeandel PY, Kanny G, Launay D, Maillard H, Martin L, Masseur A, Ollivier Y, Sobel A, Aygoren-Pursun E, Bas M, Bauer M, Bork K, Greve J, Magerl M, Martínez-Saguer I, Maurer M, Strassen U, Papadopoulou-Alatakaki E, Psarros F, Graff Y, Kivity S, Reshef A, Toubi E, Arcoletto F, Bova M, Cicardi M, Nconi PM, Marone G, Montinaro V, Triggiani M, Zanichelli A, Baeza ML, Caballero T, Cabañas R, Guilarte M, Hernández D,

- de Larramendi CH, Lleonart R, Lobera T, Marques L, Pedro BSD, Bjorkander J, Bethune C, Garcez T, Longhurst HJ. Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey. *Clin Transl Allergy.* 2019; 9: 37. Article. IF: 5.129; Q1
- Carr DF, Wang CW, Bellón T, Ressel L, Nwike G, Shrivastava V, Bergfeld W, Jorgensen AL, Chung WH, Pirmohamed M. Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. *Brit J Dermatol.* 2019; 181(1): 166-74. Article. IF: 7; D1
- Craig T, Zuraw B, Longhurst H, Cicardi M, Bork K, Grattan C, Katelaris C, Sussman G, Keith PK, Yang W, Hebert J, Hanzlikova J, Staubach-Renz P, Martínez-Saguer I, Magerl M, Aygoren-Pursun E, Farkas H, Reshef A, Kivity S, Neri S, Crisan I, Caballero T, Baeza ML, Hernández MD, Li H, Lumry W, Bernstein JA, Hussain I, Anderson J, Schwartz LB, Jacobs J, Manning M, Levy D, Riedl M, Christiansen S, Feuer-senger H, Pragst I, Mycroft S, Pawaskar D, Jacobs I,

- Zuraw BL, Cicardi M, Craig T, Longhurst H, Grattan C, Grattan C, Bork K, Kreuz W, Jacobs I, Pragst I, Herget S, Dalton S, Clement C, Mycroft S, Pawaskar D, Zhang Y, Machnig T, Waldhauser H, Feuersenger H, Lawo JP, Lang D, Hoernlein S, Mildenerger M, Foeller K, Ellis F, Wood D, Walsh M, Qu QL, Mueller-Stark K, Feussner A, Kalina U, Ma X, Rigsby S, Scheffler E, Fischer JF, Kolb C, Katelaris CH, Frankum B, Keat K, Philip B, Lee JA, Urriola N, Lee MW, Sussman GL, Levi G, Gould W, Keith PK, Ferrie P, Rosenberg E, Waserman S, Yang W, O'Quinn J, Hebert J, Gagnon R, Hanzlikova J, Vachova M, Stauerbach-Renz P, Weber A, Zimmer S, Gilfert T, Lang B, Martínez-Saguer I, Escuriola-Ettingshausen C, Magerl M, Maurer M, Metz M, Schoepke N, Altrichter S, Hawro T, Schwabe D, Graff J, Behrens F, Kohm M, Andarawewa S, Farkas H, Temesszentandras G, Kohalmi VK, Reshef A, Kidon M, Kivity S, Kadar L, Benor S, Cicardi M, Bonanni E, Wu M, Zanichelli A, Mansi M, Neri S, Rizzotto A, Giardino F, Fidone F, Crisan I, Varga M, Iftene M, Badiu-Tisa ID, Caballero T, Cabanas R, Pedrosa M, Rivero-Paparoni D, Gómez-Traseira C, Alvez A, Phillips E, Baeza ML, Prieto A, Zubeldia J, Hernández

- MD, Ibanez E, Almero R, Longhurst H, Buckland M, Grigoriadou S, Manson A, Yeatman N, Laffan J, Nasr I, Ghurye R, Rehman T, Craig T, Schaeffer C, Ghaffari G, Kelbel T, Reddy V, Buyantseva L, Mende C, Jose J, Novchicht T, Li HH, Scarupa M, Economides A, White M, Kaliner M, Ward C, Shaikh S, Johnson T, Kosh L, Dauphin P, Baker J, Persons S, Newman A, Noonan MJ, Lumry WR, Poarch KP, Tucker J, Aguilar D, Noth D, Bernstein J, Bernstein D, Evans S, Crawford M, McGuckin SD, McCollum JR, Bradley B, Wagner C, Cartwright A, Bonner J, Anderson J, Soong W, Sikora M, Lemke M, Luthin P, Youngblood B, DeBerry E, Schwartz LB, Gilbert E, Zhao W, Ward B, Álvarez A, Kumar S, Akl E, Jacobs J, Curl J, Silva K, Mostofi T, Schultz N, Manning ME, Davis A, Nelson J, Levy DS, Riedl M, Zuraw B, Christiansen SC, [Cabañas R]. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. *J Allergy Clin Immunol Pract.* 2019; 7(6): 1793-802. Article. IF: 7.574; Q1
- Fernández IS, Botello LN, Martínez B0, Gullon GR. Disseminated fungemia by *Saprochaete clavata*. *Enferm Infec Micr Cl.* 2019; 37(4): 283-4. Letter. IF:



1.654; Q4

- Fernández IS, Gil MH, Sanz MS, Gullón GR. An analysis of drug survival, effectiveness, and safety in moderate to severe psoriasis treated with ustekinumab: An observational study of 69 patients in routine clinical practice. *Actas Dermosifiliogr.* 2019; 110(3): 244-6. Letter. Not Indexed
- Fernández IS, Roldán FA, Merino LT, Fernández RS, Mera CM, Gullón GR. Ultrasound elastography images in vascular anomalies. *J Ultras Med.* 2019; 38(8): 2225-31. Article. IF: 1.759; Q2
- Fernández-Canga P, Alfageme-Roldán F, Turrín-Merino L, Roustán-Gullón G. Sonographic features and successful treatment of stump hidradenitis suppurativa. *J Dtsch Dermatol Ges.* 2019; 17(8): 826-8. Letter. IF: 3.664; Q1
- Gastaminza G, Ruiz-Canela M, Andrés-López B, Villarejo MJB, Cabañas R, García-Núñez I, Goikoetxea MJ, Laguna JJ, Lobera T, López-San Martín M, Martín-Lázaro J, Mielgo-Ballesteros R, Moreno E, Moya-Quesada MD, Ortega-Rodríguez N, Rojas-Pérez-Ezquerro P, Rosado A, Salas M, Sánchez-Morillas L, Vila-Albelda C, Corominas M. Quality of life in patients with allergic reactions to medications: Influence of a drug allergy evaluation. *J Allergy Clin Immunol Pract.* 2019; 7(8): 2714-21. Article. IF: 7.574; Q1
- Gil M, Rodríguez-Miguel A, Montoya-Catala H, González-González R, Álvarez-Gutiérrez A, Rodríguez-Martín S, García-Rodríguez LA, de Abajo FJ. Validation study of colorectal cancer diagnosis in the Spanish primary care database, BIFAP. *Pharmacoepidem Dr S.* 2019; 28(2): 209-16. Article. IF: 2.918; Q2
- Marqués-Mejías MA, Cabañas R, Ramírez E, Domínguez-Ortega J, Fiandor A, Trigo E, Quirce S, Bellón T. Lymphocyte transformation test (LTT) in allergy to benzimidazole: A promising approach. *Front Pharmacol.* 2019; 10: 469. Article. IF: 4.225; Q1
- Mockenhaupt M, Wang CW, Hung SI, Sekula P, Sch-

- midt AH, Pan RY, Chen CB, Dunant A, Le Gouvello S, Schumacher M, Valeyrie-Allanore L, Bellón T, Kardaun SH, Jan YS, Chung WH, Roujeau JC. HLA-B\*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. *Allergy.* 2019; 74(11): 2227-30. Letter. IF: 8.706; D1
- Monge-Ortega OP, Domínguez-Ortega J, González-Muñoz M, Cabañas R, Lluch-Bernal MM, Fiandor A, Bravo-Gallego LY, Quirce S. Delayed allergic reaction to furosemide with a positive lymphocyte transformation test. *Rev Alerg Mex.* 2019; 66(2): 254-6. Article. Not indexed
- Moreno-Arrones OM, Alfageme F, Alegre A, Roustán G. Ultrasonographic characteristics of frontal fibrosing alopecia. *Int J Trichology.* 2019; 11(4): 183-4. Article. Not Indexed
- Movsisyan M, Fiandor A, González-Muñoz M, Quirce S, Bellón T, Hakobyan A, Marqués-Mejías MA, Domínguez-Ortega J, Cabañas R. The lymphocyte transformation test is useful in the diagnosis of fixed drug eruption induced by etoricoxib. *J Invest Allerg Clin.* 2019; 29(4): 307-9. Editorial Material. IF: 3.488; Q2
- Pan RY, Chu MT, Wang CW, Lee YS, Lemonnier F, Michels AW, Schutte R, Ostrov DA, Chen CB, Phillips EJ, Mallal SA, Mockenhaupt M, Bellón T, Tassaneeyakul W, White KD, Roujeau JC, Chung WH, Hung SI. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. *Nat Commun.* 2019; 10: 3569. Article. IF: 12.121; D1
- Roustán G. Hidradenitis suppurativa: Need for early diagnosis and management of the disease and associated conditions. *Actas Dermosifiliogr.* 2019; 110(4): 261. Editorial Material. Not Indexed
- Salguero-Fernández I, de Domingo MAG, Suárez D, Roustán-Gullón G. Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect? *Clin Exp Dermatol.* 2019; 44(3): E41-3. Letter. IF: 1.977; Q3

- Vilas-Sueiro A, Alfageme F, Salguero I, de las Heras C, Roustan G. Ex vivo high-frequency ultrasound for assessment of basal cell carcinoma. *J Ultras Med.* 2019; 38(2): 529-31. Article. IF: 1.759; Q2
- Zubiaur AG, Alfageme F, López-Negrete E, Roustan G. Type 3 external occipital protuberance (Spine Type): Ultrasonographic diagnosis of an uncommon cause of subcutaneous scalp-pseudotumor in adolescents. *Actas Dermosifiliogr.* 2019; 110(9): 774-5. Letter. Not Indexed

## Research projects

**Bellón Heredia T.** Contrato Miguel Servet Estabilizado I2. ISCIII. 2007-2025.

**Managment centre:** FIBHULP

**Bellón Heredia T.** Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodialisis basadas en polysulfona. Nipro Europe NV. 2017-Ongoing.

**Managment centre:** FIBHULP

**Bellón Heredia T.** Enfermedad por CMV después del trasplante renal. Importancia de la monitorización inmunológica: respuesta específica T CD8 y expresión de CD94/NKG2C en relación con el rechazo. Roche Pharma S.A. 2010-Ongoing.

**Managment centre:** FIBHULP

**Bellón Heredia T.** Formación en investigación. SYF Galenus Centre S.L. 2015-Ongoing.

**Managment centre:** FIBHULP

**Bellón Heredia T.** Impacto de los inhibidores de calcineurina sobre linfocitos efectores citotóxi-

cos en síndrome de Stevens-Johnson/ necrólisis epidérmica tóxica de análisis de IL-15 como biomarcador (PI18/00718). ISCIII. 2019-2021.

**Managment centre:** FIBHULP

**Sanz Minguela B.** Contrato Estabilización Técnicos de Apoyo. ISCIII. 2008-2025.

**Managment centre:** FIBHULP

## Patents and trademarks

**Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R,** inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1,6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

**Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R,** inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

**Sánchez Niño MD, Ortiz Arduán A;** FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medication for treating chronic kidney disease and method for screening compounds. 2014 January 27. P201430081, PCT/ES2015/070039;